ClearPoint Neuro (NASDAQ:CLPT) Announces Quarterly Earnings Results

ClearPoint Neuro (NASDAQ:CLPT) posted its earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.09), FiscalAI reports. ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The company had revenue of $10.88 million for the quarter, compared to the consensus estimate of $12.73 million.

Here are the key takeaways from ClearPoint Neuro’s conference call:

• Q2 revenue increased 18% year over year to $10.9 million, helped by IRRAflow, higher operating-room procedural volumes, and increased placement of ClearPoint, Prism, and IRRAflow equipment. Gross margin also improved to 62% from 60%.
• Management raised the priority of commercial readiness after partner regulatory updates suggested potentially faster paths to Phase III enrollment and approval. ClearPoint expects 10–15 partner trials to enroll patients over the next 18 months and is expanding clinical support internationally.
• The company took possession of its 30,000-square-foot CAL preclinical facility and signed its first multimillion-dollar GLP services statement of work, expected to be completed in the first half of 2027. Management believes the facility could eventually support more than $60 million in annual revenue versus roughly $8 million of prior capacity.
• ClearPoint reduced its 2026 revenue guidance to $48 million–$52 million as it shifts spending toward clinical support, regulatory expansion, CAL equipment, focused ultrasound, robotics, and Harmony software rather than traditional sales expansion. Cash declined to $29.4 million at June 30 after $15 million of operating cash burn through the first half, although management expects burn to decrease in the second half.
• Management estimates high-teens to approximately 20% revenue growth in 2027, with upside from CAL utilization, potential commercial approvals, and stocking orders from pharmaceutical partners. Commercial procedures could generate approximately $12,000–$15,000 per patient on average, with certain programs such as uniQure’s estimated at $15,000–$25,000.

ClearPoint Neuro Stock Performance

Shares of NASDAQ:CLPT traded up $0.44 during trading on Monday, hitting $15.38. The company’s stock had a trading volume of 703,704 shares, compared to its average volume of 732,224. The company has a debt-to-equity ratio of 2.63, a current ratio of 5.79 and a quick ratio of 4.88. The firm has a market cap of $461.25 million, a price-to-earnings ratio of -15.23 and a beta of 1.23. The company has a 50-day moving average of $15.38 and a 200-day moving average of $13.05. ClearPoint Neuro has a 12 month low of $8.27 and a 12 month high of $30.10.

Wall Street Analyst Weigh In

CLPT has been the topic of a number of research analyst reports. B. Riley Financial increased their price objective on shares of ClearPoint Neuro from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Friday, July 17th. Finally, Stifel Nicolaus set a $16.00 target price on shares of ClearPoint Neuro in a research note on Tuesday, June 9th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $23.00.

Insider Buying and Selling at ClearPoint Neuro

In other news, Director Lynnette C. Fallon sold 5,091 shares of ClearPoint Neuro stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $11.14, for a total transaction of $56,713.74. Following the transaction, the director owned 48,227 shares in the company, valued at $537,248.78. This trade represents a 9.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Matthew B. Klein sold 16,000 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $11.59, for a total transaction of $185,440.00. Following the sale, the director directly owned 46,935 shares of the company’s stock, valued at approximately $543,976.65. The trade was a 25.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 108,349 shares of company stock valued at $1,796,118. 6.94% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ClearPoint Neuro

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in ClearPoint Neuro by 1.5% during the third quarter. Vanguard Group Inc. now owns 1,497,637 shares of the company’s stock valued at $32,634,000 after purchasing an additional 22,517 shares during the period. Millennium Management LLC lifted its position in shares of ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after buying an additional 452,043 shares in the last quarter. State Street Corp lifted its position in shares of ClearPoint Neuro by 30.1% during the 4th quarter. State Street Corp now owns 628,061 shares of the company’s stock valued at $8,592,000 after buying an additional 145,411 shares in the last quarter. FirstWave Capital Management LLC bought a new position in shares of ClearPoint Neuro during the 4th quarter valued at approximately $4,971,000. Finally, UBS Group AG increased its holdings in ClearPoint Neuro by 132.1% in the 3rd quarter. UBS Group AG now owns 360,705 shares of the company’s stock worth $7,860,000 after acquiring an additional 205,295 shares in the last quarter. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.